Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of GUARD.ST is 1.8 and suggests 71% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell